Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.
Bárcena R, Moreno A, Rodríguez-Gandía MA, Albillos A, Arocena C, Blesa C, García-Hoz F, Graus J, Nuño J, López-Hervás P, Gajate L, Martínez A, Bermejo T, Mateos ML, Del Campo S; Hospital Ramón y Cajal Liver Transplant Group.
Bárcena R, et al.
J Hepatol. 2013 Mar;58(3):421-6. doi: 10.1016/j.jhep.2012.10.009. Epub 2012 Oct 13.
J Hepatol. 2013.
PMID: 23073223